Diosmin: Difference between revisions

Diosmin
Clinical data
ATC code	C05CA03 (WHO) ;
Identifiers
CAS Number	520-27-4;
PubChem CID	5281613;
CompTox Dashboard (EPA)	DTXSID4045892 ;
ECHA InfoCard	100.007.537
Chemical and physical data
Formula	C28H32O15
Molar mass	608.545

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 16:32, 2 February 2007

To meet Wikipedia's quality standards, this article or section may require cleanup.
Please discuss this issue on the talk page, or replace this tag with a more specific message. Editing help is available.
This article has been tagged since April 2006.

Diosmin is a semisynthetic phlebotropic drug, a member of the flavonoid family.It is considered first-line therapy (with Hesperidin) to control internal hemorrhoidal (Piles) symptoms. It is an oral phlebotropic drug indicated in the treatment of venous disease, ie, chronic venous insufficiency (CVI) and all grades of hemorrhoidal disease (HD). Either in acute or chronic hemorrhoids, or as a valuable equivalent to rubber-band ligation in combination with fiber supplement), or as an adjuvant therapy to hemorrhoidectomy, in order to reduce secondary bleeding, it provides rapid and sutained relief.

Diosmin fight simultaneously all the pathophysiological aspects of venous disease, affecting the veins, lymphatics, and microcirculation. It prolongs the vasoconstrictor effect of noradrenaline on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and stasis. This increases the venous return and reduces venous hyperpressure present in patients suffering from CVI.

Diosmin improves lymphatic drainage by increasing the frequency and intensity of lymphatic contractions, and by increasing the total number of functional lymphatic capillaries. Furthermore, Diosmin (with Hesperidine ) decreases the diameter of lymphatic capillaries and the intralymphatic pressure.

At the microcirculation level, Diosmin reduces capillary hyperpermeability and increases capillary resistance by protecting the microcirculation from damaging processes.

Diosmin reduces the expression of endothelial adhesion molecules (ICAM1, VCAM1), and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals and prostaglandins (PGE2, PGF2a).

This protective and reinforcing action on the venous and lymphatic system, associated with the vasculoprotective effect on the microcirculation, explains the restorative and protective efficacy of DIOSMIN WITH HESPERIDIN 500 mg in chronic venous insufficiency and hemorrhoidal disease, both of which are associated with perivascular inflammation and edema.

FDA APPROVAL OF DIOSMIN 95

Diosmin was approved by the FDA in APRIL 2000 Diosmin 95 complex (Diosmin (95/5)) was approved by the FDA for consumer consumption in SEPTEMBER 2005 Diosmin 95 complex is 95% Diosmin and 5% Hesperidin

Diosmin 95 is currently a prescription medication in Europe that has been used to treat Varicose and Spider veins. It is now available in the U.S. without a prescription. it is the same pharmaceutical product that is currently prescribed in Europe. Clinical trials of Diosmin 95 showed positivie and quick success with

Reduction of Varicose & Spider Veins
Relief from Swelling & Inflammation of the Legs
Reversal of Chronic Venous Insufficiency (vein disorders)
Relief from Leg Ulcers
Relief from Hemorrhoids

EXTERNAL LINKS

http://answers.yahoo.com/question/index?qid=20060830231437AAogvxA

@@ Line 1: / Line 1: @@
+<div class="messagebox cleanup metadata">'''To meet Wikipedia's [[:Category:Wikipedia style guidelines|quality standards]], this article or section may require [[Wikipedia:Cleanup|cleanup]].''' <br /><span style="font-size: 90%">
+Please discuss this issue on the [[Talk:{{PAGENAME}}|talk page]], or replace this tag with a [[Wikipedia:Template_messages/Cleanup#Cleanup_.E2.80.94_specific_issues|more specific message]]. [[Help:Editing|Editing help]] is available.<br />This article has been tagged since [[April 2006]].</span></div>[[Category:Cleanup from April 2006]]
+'''Diosmin''' is a [[semisynthetic]] [[phlebotropic]] [[drug]], a member of the [[flavonoid]] family.It is considered [[first-line therapy]] (with [[Hesperidin]]) to control internal [[hemorrhoidal]] (Piles) symptoms.  It is an oral phlebotropic drug indicated in the treatment of [[venous disease]], ie, chronic [[venous insufficiency]] (CVI) and all grades of hemorrhoidal disease (HD). Either in acute or chronic hemorrhoids, or as a valuable equivalent to [[rubber-band ligation]] in combination with fiber supplement), or as an adjuvant therapy to hemorrhoidectomy, in order to reduce secondary bleeding, it provides rapid and sutained relief.
+Diosmin fight simultaneously all the pathophysiological aspects of venous disease, affecting the [[veins]], [[lymphatics]], and [[microcirculation]]. It prolongs the [[vasoconstrictor]] effect of [[noradrenaline]] on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and [[stasis]]. This increases the [[venous return]] and reduces venous hyperpressure present in patients suffering from CVI.
+Diosmin improves lymphatic drainage by increasing the frequency and intensity of lymphatic contractions, and by increasing the total number of functional lymphatic capillaries. Furthermore, Diosmin (with Hesperidine ) decreases the diameter of lymphatic capillaries and the intralymphatic pressure.
+At the microcirculation level, Diosmin reduces capillary hyperpermeability and increases capillary resistance by protecting the microcirculation from damaging processes.
+Diosmin reduces the expression of [[endothelial adhesion molecules]] ([[ICAM1]], [[VCAM1]]), and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals and [[prostaglandins]] ([[PGE2]], [[PGF2a]]).
+This protective and reinforcing action on the venous and lymphatic system, associated with the vasculoprotective effect on the microcirculation, explains the restorative and protective efficacy of DIOSMIN WITH HESPERIDIN 500 mg in chronic venous insufficiency and hemorrhoidal disease, both of which are associated with perivascular inflammation and [[edema]].
+'''FDA APPROVAL OF DIOSMIN 95'''
+----
+Diosmin was approved by the [[FDA|FDA]]  in APRIL 2000
+Diosmin 95 complex (Diosmin (95/5)) was approved by the FDA for consumer consumption in SEPTEMBER 2005
+Diosmin 95 complex is 95% Diosmin and 5% [[Hesperidin|Hesperidin]]
+Diosmin 95 is currently a prescription medication in Europe that has been used to treat [[Varicose|Varicose]] and [[Telangiectasia|Spider veins]]. It is now available in the U.S. without a prescription. it is the same pharmaceutical product that is currently prescribed in Europe. Clinical trials of Diosmin 95 showed positivie and quick success with
+* Reduction of Varicose & Spider Veins
+* Relief from Swelling & Inflammation of the Legs
+* Reversal of Chronic Venous Insufficiency (vein disorders)
+* Relief from Leg Ulcers
+* Relief from [[Hemorrhoids|Hemorrhoids]]
+'''EXTERNAL LINKS'''
+----
+http://answers.yahoo.com/question/index?qid=20060830231437AAogvxA
+----
 {{Drugbox|
 |IUPAC_name =
@@ Line 18: / Line 58: @@
 | routes_of_administration=
 }}
-<div class="messagebox cleanup metadata">'''To meet Wikipedia's [[:Category:Wikipedia style guidelines|quality standards]], this article or section may require [[Wikipedia:Cleanup|cleanup]].''' <br /><span style="font-size: 90%">
-Please discuss this issue on the [[Talk:{{PAGENAME}}|talk page]], or replace this tag with a [[Wikipedia:Template_messages/Cleanup#Cleanup_.E2.80.94_specific_issues|more specific message]]. [[Help:Editing|Editing help]] is available.<br />This article has been tagged since [[April 2006]].</span></div>[[Category:Cleanup from April 2006]]
-'''Diosmin''' is a [[semisynthetic]] [[phlebotropic]] [[drug]], a member of the [[flavonoid]] family.It is considered [[first-line therapy]] (with [[Hesperidin]]) to control internal [[hemorrhoidal]] (Piles) symptoms.  It is an oral phlebotropic drug indicated in the treatment of [[venous disease]], ie, chronic [[venous insufficiency]] (CVI) and all grades of hemorrhoidal disease (HD). Either in acute or chronic hemorrhoids, or as a valuable equivalent to [[rubber-band ligation]] in combination with fiber supplement), or as an adjuvant therapy to hemorrhoidectomy, in order to reduce secondary bleeding, it provides rapid and sutained relief.
-Diosmin fight simultaneously all the pathophysiological aspects of venous disease, affecting the [[veins]], [[lymphatics]], and [[microcirculation]]. It prolongs the [[vasoconstrictor]] effect of [[noradrenaline]] on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and [[stasis]]. This increases the [[venous return]] and reduces venous hyperpressure present in patients suffering from CVI.
-Diosmin improves lymphatic drainage by increasing the frequency and intensity of lymphatic contractions, and by increasing the total number of functional lymphatic capillaries. Furthermore, Diosmin (with Hesperidine ) decreases the diameter of lymphatic capillaries and the intralymphatic pressure.
-At the microcirculation level, Diosmin reduces capillary hyperpermeability and increases capillary resistance by protecting the microcirculation from damaging processes.
-Diosmin reduces the expression of [[endothelial adhesion molecules]] ([[ICAM1]], [[VCAM1]]), and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals and [[prostaglandins]] ([[PGE2]], [[PGF2a]]).
-This protective and reinforcing action on the venous and lymphatic system, associated with the vasculoprotective effect on the microcirculation, explains the restorative and protective efficacy of DIOSMIN WITH HESPERIDIN 500 mg in chronic venous insufficiency and hemorrhoidal disease, both of which are associated with perivascular inflammation and [[edema]].